ARCTURUS THERAPEUTICS HOLDINGS INC. Proceeds from Issuance of Debt
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Proceeds from Issuance of Debt of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2026-08-06
- ARCTURUS THERAPEUTICS HOLDINGS INC. proceeds from issuance of debt for the quarter ending 2026-06-30 was $0.00.
- ARCTURUS THERAPEUTICS HOLDINGS INC. proceeds from issuance of debt for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. proceeds from issuance of debt for the quarter ending 2025-12-31 was $0.00.
- ARCTURUS THERAPEUTICS HOLDINGS INC. proceeds from issuance of debt for the quarter ending 2025-09-30 was $0.00.
- ARCTURUS THERAPEUTICS HOLDINGS INC. proceeds from issuance of debt for fiscal 2025 was $15.00M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. proceeds from issuance of debt for fiscal 2023 was $20.00M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. proceeds from issuance of debt for fiscal 2021 was $46.60M.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 6 month | Proceeds from Issuance of Debt 9 month | Proceeds from Issuance of Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $15.00M 10-K · filed 2026-03-03 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $15.00M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $15.00M 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $15.00M 10-Q · filed 2026-05-07 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $20.00M 10-K · filed 2026-03-03 | ||
| 2023-09-30 | $20.00M 10-Q · filed 2024-11-07 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 derived: sum of 3 quarters · filed 2024-03-14 | $46.60M 10-K · filed 2024-03-14 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $46.60M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $46.60M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $46.60M 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |